112 related articles for article (PubMed ID: 25884371)
1. American Society of Clinical Oncology/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Clinical Practice Guideline Upcoming Modifications: Proof That Clinical Practice Guidelines Are Living Documents.
Hammond ME; Hicks DG
Arch Pathol Lab Med; 2015 Aug; 139(8):970-1. PubMed ID: 25884371
[No Abstract] [Full Text] [Related]
2. National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer.
Rakha EA; Pigera M; Shaaban A; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
J Clin Oncol; 2015 Apr; 33(11):1301-2. PubMed ID: 25753440
[No Abstract] [Full Text] [Related]
3. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
[TBL] [Abstract][Full Text] [Related]
4. The American Society of Clinical Oncology-College of American Pathologists Guideline Update for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Schnitt SJ; Tarantino P; Collins LC
Arch Pathol Lab Med; 2023 Sep; 147(9):991-992. PubMed ID: 37303241
[No Abstract] [Full Text] [Related]
5. Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? American Society of Clinical Oncology/College of American Pathologists Guidelines 2007, 2013, and 2018.
Murray C; D'Arcy C; Gullo G; Flanagan L; Quinn CM
Arch Pathol Lab Med; 2019 Apr; 143(4):412-413. PubMed ID: 30605368
[No Abstract] [Full Text] [Related]
6. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
7. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
8. Implementation of the 2018 Human Epidermal Growth Factor Receptor 2 Guideline by American Society of Clinical Oncology/College of American Pathologists Will Reduce False-Positive Tests.
Martin V; Valera A; De Joffrey M; Banfi S; Mazzucchelli L
Arch Pathol Lab Med; 2019 Apr; 143(4):411-412. PubMed ID: 30605369
[No Abstract] [Full Text] [Related]
9. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary.
Wolff AC; Hammond MEH; Allison KH; Harvey BE; McShane LM; Dowsett M
J Oncol Pract; 2018 Jul; 14(7):437-441. PubMed ID: 29920138
[No Abstract] [Full Text] [Related]
10. Reply to E.A. Rakha et al.
Wolff AC; Hammond ME; Hicks DG; Allison KH; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Dowsett M; McShane LM; Hayes DF
J Clin Oncol; 2015 Apr; 33(11):1302-4. PubMed ID: 25753441
[No Abstract] [Full Text] [Related]
11. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology/College of American Pathologists guidelines should be scientifically validated.
Lombardo JF
Arch Pathol Lab Med; 2007 Oct; 131(10):1510; author reply 1510-1. PubMed ID: 17922576
[No Abstract] [Full Text] [Related]
13. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
[TBL] [Abstract][Full Text] [Related]
14. 2013 update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers.
Lambein K; Van Bockstal M; Denys H; Libbrecht L
J Clin Oncol; 2014 Jun; 32(17):1856-7. PubMed ID: 24778399
[No Abstract] [Full Text] [Related]
15. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
Shah MV; Wiktor AE; Meyer RG; Tenner KS; Ballman KV; Green SJ; Sukov WR; Ketterling RP; Perez EA; Jenkins RB
J Clin Oncol; 2016 Oct; 34(29):3502-3510. PubMed ID: 27458302
[TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
Hanna WM; Slodkowska E; Lu FI; Nafisi H; Nofech-Mozes S
J Clin Oncol; 2017 Sep; 35(26):3039-3045. PubMed ID: 28445098
[TBL] [Abstract][Full Text] [Related]
17. Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.
Xu FP; Wang K; Xu J; Chen J; Zhang YF; Wu HM; Zhang MH; Long XX; Luo XL; Zhang KP; Lin DY; Liu YH
Breast Cancer Res Treat; 2017 Dec; 166(3):757-764. PubMed ID: 28861637
[TBL] [Abstract][Full Text] [Related]
18. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
19. Interpretation of human epidermal growth factor receptor 2 (HER2) in situ hybridization assays using 2013 update of American Society of Clinical Oncology/College of American Pathologists HER2 Guidelines.
Bhargava R; Dabbs DJ
J Clin Oncol; 2014 Jun; 32(17):1855. PubMed ID: 24778404
[No Abstract] [Full Text] [Related]
20. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
